P
Peter C. Taylor
Researcher at University of Oxford
Publications - 397
Citations - 19020
Peter C. Taylor is an academic researcher from University of Oxford. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 63, co-authored 359 publications receiving 16347 citations. Previous affiliations of Peter C. Taylor include HealthPartners & University of Cambridge.
Papers
More filters
Journal ArticleDOI
Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events.
Floyd D. Loop,Bruce W. Lytle,Delos M. Cosgrove,Robert W. Stewart,Marlene Goormastic,G W Williams,Leonard A.R. Golding,Carl C. Gill,Peter C. Taylor,W C Sheldon +9 more
TL;DR: It was found that patients who had only vein grafts had a 1.61 times greater risk of death throughout the 10 years, as compared with those who received an internal-mammary-artery graft.
Journal ArticleDOI
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Ravinder N. Maini,Peter C. Taylor,Jacek Szechiński,Karel Pavelka,J Broll,G Balint,Paul Emery,F Raemen,Jørgen Holm Petersen,Josef S Smolen,D Thomson,Tadamitsu Kishimoto +11 more
TL;DR: The results indicate that targeted blockade of IL-6 signaling is a highly efficacious and promising means of decreasing disease activity in RA.
Journal ArticleDOI
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor,Edward C. Keystone,Désirée van der Heijde,Michael E. Weinblatt,Liliana del Carmen Morales,Jaime Reyes Gonzaga,Sergey Yakushin,T. Ishii,K. Emoto,Scott Beattie,Vipin Arora,Carol L. Gaich,Terence Rooney,Douglas E Schlichting,William L. Macias,Stephanie de Bono,Yoshiya Tanaka +16 more
TL;DR: In patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.
Journal ArticleDOI
Neutralizing monoclonal antibodies for treatment of COVID-19.
Peter C. Taylor,Andrew C. Adams,Matthew M. Hufford,Inmaculada de la Torre,Kevin L. Winthrop,Robert L. Gottlieb,Robert L. Gottlieb +6 more
TL;DR: In this article, neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical trials.
Journal ArticleDOI
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.
Peter C. Taylor,A. M. Peters,Ewa M. Paleolog,P T Chapman,M J Elliott,R V McCloskey,M Feldmann,Ravinder Nath Maini +7 more
TL;DR: TNFalpha blockade reduces synovial expression of the chemokines IL-8 and MCP-1 and diminishes inflammatory cell migration into RA joints and confirms the hypothesis that in rheumatoid arthritis, tumor necrosis factor alpha plays a critical role in regulating leukocyte trafficking and chemokine levels.